It is crucial to understand that the most of the damage caused by brain injury does not occur upon initial impact to the head, but rather as a consequence of secondary brain injury.

Medicortex Finland R&D Plan

Our R&D plan consists of two programs. Currently more active is the Biomarker program including development of the diagnostic kit. Once the Biomarker program is advanced we will focus on the Drug development program. All the requirements of clinical trials will be rigorously followed in each phase of the development.

1. Progression of the Biomarker program

Picture1


2. The outline of the Drug development program

Infograph Copyright


 

Medicortex Infografiikka Final
50 KB, updated on Sep 24th 2014